Alector (STU:0Z2) Valuation Rank


STU:0Z2 Alector Inc STU:0Z2
31 GF Score
Price €1.78
GF Value €0.63
! 7 Warning Signs
View Full Analysis

What is Alector Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Alector Valuation Rank Related Terms

STU:0Z2
31GF Score
Alector Inc STU:0Z2
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Alector (STU:0Z2) Overvalued in 2026?

Based on GuruFocus' analysis, Alector stock appears to be overvalued. The current stock price of €1.78 is trading 182.4% above its estimated GF Value™ of €0.63.

Key valuation signals for STU:0Z2:

  • Valuation Rank:
  • GF Value™: €0.63 vs. price of €1.78 (182.4% above fair value)
  • GF Score™: 31/100 with 7 warning signs

No single metric tells the full story. See the STU:0Z2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alector Business Description

Other Exchanges ALEC:USA
Address 131 Oyster Point Boulevard, Suite 600, South San Francisco, CA, USA, 94080
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.
31GF Score

Get the complete analysis for STU:0Z2

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.78
Price
€0.63
GF Value